Search

Cisplatin has become a major clinical drug because of its proven efficacy against many tumors. It exhibits excellent activity against testicular tumors and is responsible for remission rates of about 50% in ovarian cancer. It is also used in combination chemotherapy for a variety of other tumors. As with all anticancer drugs, many tumors are inherently resistant to the therapy or acquire resistance after an initial treatment. Because of the high remission rate in ovarian tumors, this disease has become noted for the high incidence of recurrent tumors. It is quite possible that the mechanisms of inherent and acquired resistance are one and the same, but evidence for this requires further research.

The treatment of Glomerulonephritides (GN) is controversial (1). Immunosuppressive (IS) treatment is very effective in controlling GN of systemic diseases, such as SLE (2), but it still yields conflicting results in membranous (M) GN (3,4), and is considered ineffective in Membranoprolipherative GN (MPGN). Therefore we started the present study with a flexible IS regimen combining high doses of Prednisone (PDN) and Cyclophosphamide (CPM) for a prolonged period of time.

It has been more than 20 years since 6-mercaptopurine was successfully used for the first time in the treatment of malignant trophoblastic neoplasms in the Capital Hospital in 1958. Since then, a total of four effective drugs have been found, and a dramatic improvement in prognosis of the patients has been achieved, resulting in permanent cure of this group of tumors. The overall results of treatment were reported in 1979 (1). To provide a general principle for the selection of a proper chemotherapeutic agent for clinical use, it is mandatory to evaluate each drug individually. The purpose of this paper is to present the therapeutic results of 5-fluorouracil used as a single agent in the treatment of malignant trophoblastic neoplasms.

The last several years have witnessed significant improvements in the remission rate and survival of adults with leukemia. Infection, however, remains a major problem for these patients, particularly when they are granulocytopenic. During the last decade, considerable strides in supportive care have helped to reduce infection-related morbidity and mortality. The principles employed are unique to the compromised host and require a departure from those considered standard in general infectious disease. An appreciation of the approach to the diagnosis, management and prevention of infection in the patient with acute leukemia is essential for the clinical oncologist and infectious disease specialist. In this chapter we will focus on the emerging body of data which has defined the boundaries and principles of management. In so doing, we will highlight the new developments in the patterns of infection and the agents available to treat them. Our goal is to place current data and controversies in focus and perspective.